Intravitreal bevacizumab in a patient with a macular star in malignant hypertension.
OBJECTIVE
To report a case of retinopathy secondary to malignant hypertension showing a macular star, which responded favorably to a single intravitreal injection of bevacizumab (IVB).


METHODS
A 46-year-old man with malignant hypertension showing incomplete macular star in his right eye with best-corrected visual acuity (BCVA) of 20/32 underwent IVB.


RESULTS
Subsequent examinations revealed a progressive resolution of the macular star with functional recovery over the follow-up. In particular, at the 9-month examination BCVA was 20/20, fundus biomicroscopy disclosed resolution of the macular star, and the retinal sensitivity improved remarkably.


CONCLUSIONS
Intravitreal injection of bevacizumab can be a useful approach to treat the exudative manifestations of malignant hypertension.
Zucchiatti
Ilaria
I
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy.
Iacono
Pierluigi
P
Battaglia Parodi
Maurizio
M
Cascavilla
Maria Lucia
ML
Kontadakis
Dimitris Stelios
DS
Bandello
Francesco
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001794:Blood Pressure / Q000502:physiology; D005451:Fluorescein Angiography; D006801:Humans; D006974:Hypertension, Malignant / Q000150:complications*; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab